VivoSeq
Infectious Disease

Cytomegalovirus Retinitis

10

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Cytomegalovirus Retinitis is an early-stage landscape with 10 programs across 8 companies. The most active players are Gilead, Agouron Pharmaceuticals, Novartis. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 2A

Agouron Pharmaceuticals

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2E

Exela Pharma Sciences, LLC.

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

9 of 10 classified programs — the dominant modality here.

10%ALL OTHERSProtein / enzyme110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed12 · 92%
Recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Clinical Study of High Concentration Ganciclovir Eye Drops in the Treatment of Cytomegalovirus Retinitis
Recruiting·TTianjin Medical University·Phase 1·NCT05911503·15 enrolled
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·N/A·NCT00002187
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 2·NCT00002156·194 enrolled
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Completed·AAgouron Pharmaceuticals·Phase 2·NCT00002169
A Randomized, Controlled Study of the Safety and Preventive Efficacy of Oral Ganciclovir When Used in Conjunction With An Intravitreal Ganciclovir Implant in the Treatment of Cytomegalovirus Retinitis
Completed·Roche logoRoche·N/A·NCT00002134·450 enrolled
Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000693·25 enrolled
Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
Completed·JJohns Hopkins Bloomberg School of Public Health·Phase 3·NCT00000134·279 enrolled
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
Completed·Gilead logoGilead·N/A·NCT00002142·100 enrolled
A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000688·180 enrolled
Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis
Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004794·90 enrolled
A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS
Completed·Roche logoRoche·N/A·NCT00002257·150 enrolled
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
Completed·Roche logoRoche·N/A·NCT00002247·225 enrolled
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
Completed·Roche logoRoche·N/A·NCT00002034·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)